The University of Chicago Header Logo

Richard Schilsky

Concepts (773)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Medical Oncology
67
2023
356
13.740
Why?
Neoplasms
164
2023
2868
13.010
Why?
Antineoplastic Agents
95
2024
2347
10.750
Why?
Clinical Trials as Topic
66
2021
1166
8.160
Why?
Precision Medicine
28
2021
390
6.110
Why?
Colorectal Neoplasms
36
2023
919
4.520
Why?
Antineoplastic Combined Chemotherapy Protocols
78
2023
2424
4.480
Why?
Molecular Targeted Therapy
18
2021
266
4.450
Why?
Fluorouracil
46
2017
556
2.850
Why?
Humans
347
2024
85610
2.630
Why?
Drug Approval
13
2018
62
2.510
Why?
United States
71
2022
6585
2.390
Why?
Biomarkers, Tumor
24
2019
1458
2.380
Why?
Biomedical Research
17
2021
373
2.320
Why?
Societies, Medical
19
2021
570
2.270
Why?
Biosimilar Pharmaceuticals
4
2022
20
2.140
Why?
Melanoma
3
2023
451
2.060
Why?
Mutation
15
2024
3946
1.960
Why?
Delivery of Health Care
8
2020
418
1.950
Why?
Antimetabolites, Antineoplastic
17
2011
236
1.880
Why?
Breast Neoplasms
33
2024
2855
1.790
Why?
Research Design
22
2023
589
1.670
Why?
Leucovorin
29
2017
218
1.670
Why?
Carcinoma, Non-Small-Cell Lung
14
2023
1071
1.570
Why?
Colonic Neoplasms
10
2018
550
1.500
Why?
Lung Neoplasms
25
2023
2248
1.430
Why?
Deoxycytidine
13
2011
237
1.400
Why?
Patient Selection
12
2018
683
1.320
Why?
Immunotherapy
11
2019
620
1.290
Why?
Patient Participation
4
2016
212
1.270
Why?
United States Food and Drug Administration
15
2019
126
1.260
Why?
Disclosure
4
2019
108
1.220
Why?
Genomics
7
2019
702
1.170
Why?
Uracil
11
2002
70
1.150
Why?
Randomized Controlled Trials as Topic
19
2020
843
1.140
Why?
Genes, ras
3
2017
96
1.110
Why?
Evidence-Based Medicine
4
2020
426
1.110
Why?
Drug Design
8
2010
124
1.010
Why?
Genetic Testing
4
2020
530
0.980
Why?
Cetuximab
4
2020
113
0.980
Why?
Early Detection of Cancer
7
2020
383
0.970
Why?
Aged
115
2021
18254
0.940
Why?
Data Accuracy
1
2023
30
0.930
Why?
Gastrointestinal Neoplasms
6
2014
104
0.910
Why?
Information Dissemination
5
2023
103
0.850
Why?
Middle Aged
118
2021
24842
0.840
Why?
Female
142
2024
44181
0.830
Why?
Trastuzumab
6
2023
65
0.830
Why?
Antineoplastic Agents, Immunological
2
2021
185
0.820
Why?
ErbB Receptors
3
2015
485
0.820
Why?
Antibodies, Monoclonal
13
2022
1373
0.810
Why?
Prostatic Neoplasms, Castration-Resistant
1
2023
104
0.810
Why?
National Cancer Institute (U.S.)
4
2020
70
0.810
Why?
fms-Like Tyrosine Kinase 3
2
2020
121
0.800
Why?
Cisplatin
25
2005
604
0.800
Why?
Antibodies, Monoclonal, Humanized
10
2023
925
0.780
Why?
Pandemics
4
2022
724
0.780
Why?
Oncologists
2
2020
35
0.780
Why?
Registries
6
2022
698
0.760
Why?
Endometrial Neoplasms
1
2023
189
0.750
Why?
Oxidoreductases
6
2002
111
0.740
Why?
Financial Support
1
2019
7
0.740
Why?
Clinical Decision-Making
5
2021
254
0.740
Why?
Rural Population
1
2020
135
0.720
Why?
Neoplasm Staging
15
2018
1929
0.720
Why?
Drug Delivery Systems
4
2011
177
0.710
Why?
Insurance Benefits
1
2019
8
0.710
Why?
Periodicals as Topic
2
2019
167
0.700
Why?
Treatment Outcome
36
2021
7908
0.700
Why?
Male
125
2023
40659
0.690
Why?
Practice Guidelines as Topic
8
2020
1024
0.690
Why?
Decision Support Systems, Clinical
2
2019
103
0.680
Why?
Cooperative Behavior
6
2015
173
0.680
Why?
Receptor, ErbB-2
5
2023
210
0.680
Why?
Drug Discovery
3
2019
103
0.680
Why?
Genome, Human
5
2017
754
0.670
Why?
Health Plan Implementation
1
2019
56
0.670
Why?
Adult
102
2021
25442
0.670
Why?
Electronic Health Records
3
2019
317
0.660
Why?
Famous Persons
1
2018
14
0.660
Why?
Drug Industry
3
2018
53
0.650
Why?
Skin Ulcer
1
2018
25
0.650
Why?
Enzyme Inhibitors
6
2002
631
0.650
Why?
Hematology
1
2018
29
0.650
Why?
Pneumonia, Viral
2
2020
311
0.650
Why?
Coronavirus Infections
2
2020
296
0.650
Why?
Health Care Costs
5
2017
237
0.650
Why?
Clinical Trials, Phase III as Topic
10
2018
168
0.650
Why?
Proto-Oncogene Proteins B-raf
4
2023
137
0.640
Why?
Off-Label Use
2
2015
16
0.640
Why?
Community Health Services
1
2019
80
0.640
Why?
Decision Support Techniques
2
2016
160
0.630
Why?
Value-Based Purchasing
1
2017
4
0.620
Why?
Pharmacogenetics
5
2010
429
0.610
Why?
Camptothecin
10
2017
189
0.580
Why?
Leukemia
6
2013
317
0.580
Why?
Organizations
2
2013
17
0.580
Why?
Multicenter Studies as Topic
6
2016
148
0.570
Why?
Methotrexate
14
1996
249
0.560
Why?
Liver Neoplasms
6
2018
712
0.560
Why?
Chemotherapy, Adjuvant
15
2018
458
0.560
Why?
Research Support as Topic
3
2017
79
0.560
Why?
Infusions, Intravenous
24
2015
430
0.530
Why?
History, 20th Century
5
2020
312
0.520
Why?
Neutropenia
14
2016
214
0.520
Why?
Drug Costs
1
2015
62
0.520
Why?
Choice Behavior
1
2016
160
0.520
Why?
Health Care Sector
1
2014
13
0.510
Why?
Kidney Neoplasms
6
2012
614
0.500
Why?
Authorship
1
2014
24
0.500
Why?
Antineoplastic Agents, Phytogenic
7
2014
276
0.500
Why?
Neoplasms, Glandular and Epithelial
1
2015
74
0.490
Why?
Data Mining
1
2014
42
0.490
Why?
Conflict of Interest
1
2014
67
0.490
Why?
Research
5
2009
251
0.480
Why?
Adenocarcinoma
8
2011
1159
0.480
Why?
Neoplasm Metastasis
11
2021
1053
0.470
Why?
Comparative Effectiveness Research
2
2018
53
0.470
Why?
Administration, Oral
18
2007
684
0.460
Why?
Molecular Diagnostic Techniques
3
2014
69
0.460
Why?
Physicians
2
2019
668
0.460
Why?
Reimbursement Mechanisms
3
2019
39
0.460
Why?
Predictive Value of Tests
6
2016
1664
0.450
Why?
Gastrointestinal Stromal Tumors
1
2012
23
0.450
Why?
Protein-Tyrosine Kinases
2
2022
302
0.440
Why?
Cancer Vaccines
4
2015
156
0.440
Why?
Data Collection
3
2010
371
0.440
Why?
Quality of Health Care
4
2021
379
0.440
Why?
Drug Administration Schedule
25
2015
917
0.430
Why?
National Institutes of Health (U.S.)
3
2008
115
0.430
Why?
Circadian Rhythm
1
2015
300
0.430
Why?
Pancreatic Neoplasms
7
2014
640
0.420
Why?
Surveys and Questionnaires
3
2021
2452
0.420
Why?
Dose-Response Relationship, Drug
23
2014
1959
0.410
Why?
Practice Patterns, Physicians'
2
2014
575
0.410
Why?
Hematologic Diseases
3
2011
79
0.410
Why?
History, 21st Century
3
2020
175
0.410
Why?
Paclitaxel
9
2011
458
0.410
Why?
Polyglutamic Acid
7
1996
15
0.390
Why?
Patient Preference
3
2021
104
0.390
Why?
Drug-Related Side Effects and Adverse Reactions
2
2010
197
0.390
Why?
Anticarcinogenic Agents
1
2011
70
0.380
Why?
Prognosis
11
2019
3653
0.370
Why?
Aged, 80 and over
32
2019
6464
0.360
Why?
Costs and Cost Analysis
2
2020
152
0.360
Why?
Clinical Medicine
1
2009
34
0.360
Why?
Privacy
1
2009
21
0.360
Why?
Gene Expression Regulation, Neoplastic
4
2009
1196
0.360
Why?
Health Services Accessibility
4
2020
390
0.350
Why?
Time Factors
17
2018
5186
0.350
Why?
Proto-Oncogene Proteins
3
2022
645
0.350
Why?
Etoposide
7
2007
195
0.340
Why?
Hydroxyurea
9
1993
239
0.340
Why?
Placebos
2
2010
217
0.330
Why?
Forecasting
5
2020
303
0.330
Why?
Diffusion of Innovation
4
2020
71
0.320
Why?
Protein Kinase Inhibitors
1
2012
588
0.320
Why?
ras Proteins
1
2009
128
0.320
Why?
Disease-Free Survival
14
2017
1203
0.320
Why?
Imides
7
1999
26
0.320
Why?
Human Experimentation
1
2008
39
0.320
Why?
Cyclophosphamide
9
2016
299
0.320
Why?
Risk Assessment
7
2016
2243
0.320
Why?
Isoquinolines
7
1999
72
0.310
Why?
Circulating Tumor DNA
2
2018
37
0.310
Why?
Drug Evaluation
18
2007
141
0.310
Why?
Indoles
3
2022
317
0.310
Why?
Survival Analysis
13
2018
1535
0.310
Why?
Quality Assurance, Health Care
2
2008
220
0.300
Why?
Europe
4
2021
308
0.300
Why?
Guidelines as Topic
1
2008
162
0.300
Why?
Capecitabine
8
2004
87
0.290
Why?
Blood Specimen Collection
2
2018
27
0.290
Why?
Health Policy
2
2020
179
0.290
Why?
Reproducibility of Results
9
2020
2680
0.290
Why?
Biological Products
1
2008
142
0.290
Why?
Trust
3
2021
92
0.280
Why?
O(6)-Methylguanine-DNA Methyltransferase
3
2002
118
0.280
Why?
Granulocyte Colony-Stimulating Factor
6
2016
164
0.280
Why?
Lymphoma, Non-Hodgkin
4
2007
261
0.280
Why?
Cytarabine
7
1993
218
0.280
Why?
Interprofessional Relations
1
2007
121
0.280
Why?
Biomarkers
3
2008
1701
0.270
Why?
Neoplasm Recurrence, Local
9
2017
1289
0.270
Why?
Cost-Benefit Analysis
4
2016
448
0.270
Why?
Drug Synergism
10
2003
303
0.270
Why?
Prodrugs
3
2004
46
0.260
Why?
Cost of Illness
2
2016
150
0.260
Why?
Quality of Life
6
2021
1551
0.260
Why?
Attitude of Health Personnel
3
2018
635
0.250
Why?
Head and Neck Neoplasms
14
2007
1047
0.250
Why?
Health Knowledge, Attitudes, Practice
3
2019
505
0.250
Why?
Patient Safety
2
2017
209
0.250
Why?
Disease Progression
9
2018
1519
0.250
Why?
Adenoma
2
2004
231
0.250
Why?
Receptor, Fibroblast Growth Factor, Type 2
1
2024
12
0.250
Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2024
19
0.250
Why?
Survival Rate
12
2010
1855
0.250
Why?
Proto-Oncogene Proteins p21(ras)
3
2018
153
0.250
Why?
Drugs, Investigational
3
2019
37
0.240
Why?
Doxorubicin
10
2016
288
0.240
Why?
DNA, Neoplasm
3
2018
265
0.240
Why?
Cyclosporine
3
2004
234
0.240
Why?
Ipilimumab
1
2023
58
0.230
Why?
Ataxia Telangiectasia Mutated Proteins
1
2023
52
0.230
Why?
Tetrahydrofolates
4
1992
13
0.230
Why?
Positron-Emission Tomography
3
2013
325
0.220
Why?
Phthalazines
1
2023
38
0.220
Why?
Tissue Banks
1
2002
16
0.220
Why?
Clinical Trials, Phase II as Topic
6
2015
173
0.220
Why?
Guanine
2
2000
208
0.220
Why?
Biopsy
3
2017
1159
0.210
Why?
Hodgkin Disease
6
1998
176
0.210
Why?
Advisory Committees
3
2021
90
0.210
Why?
Aspirin
1
2003
154
0.210
Why?
Drug Labeling
2
2019
41
0.210
Why?
Global Health
2
2020
192
0.210
Why?
Risk Factors
7
2018
5366
0.210
Why?
Drug Screening Assays, Antitumor
3
2011
78
0.210
Why?
Financing, Government
4
2016
22
0.210
Why?
Vinblastine
5
1998
108
0.200
Why?
BRCA1 Protein
1
2023
195
0.200
Why?
Vaccination
2
2022
252
0.200
Why?
Gene Silencing
1
2002
172
0.200
Why?
Dihydrouracil Dehydrogenase (NADP)
5
2002
29
0.200
Why?
Small Cell Lung Carcinoma
1
2022
97
0.200
Why?
Carcinoma, Small Cell
3
1997
134
0.200
Why?
Cardiovascular Agents
1
2021
56
0.200
Why?
Combined Modality Therapy
10
2019
1657
0.200
Why?
Pregnancy Complications, Neoplastic
1
2000
28
0.200
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2003
238
0.190
Why?
Organoplatinum Compounds
4
2017
94
0.190
Why?
Karnofsky Performance Status
3
2018
40
0.190
Why?
Informed Consent
3
2020
265
0.190
Why?
Databases, Factual
3
2019
799
0.190
Why?
Sulfonamides
1
2022
296
0.190
Why?
Fertility
2
1992
111
0.190
Why?
Carcinoma
3
2001
432
0.190
Why?
Testis
4
1989
150
0.190
Why?
Research Report
1
2020
44
0.190
Why?
Pyridines
3
2022
309
0.190
Why?
Consensus
5
2020
327
0.190
Why?
Betacoronavirus
2
2020
254
0.190
Why?
Gene Expression Profiling
5
2019
1378
0.190
Why?
Checklist
1
2020
56
0.190
Why?
Natural Language Processing
1
2020
36
0.190
Why?
Lymphoma, Large B-Cell, Diffuse
1
2002
151
0.190
Why?
Dissent and Disputes
1
2020
28
0.190
Why?
Health Facilities
1
2020
37
0.190
Why?
Carmustine
3
2005
70
0.190
Why?
Communication
2
2021
436
0.180
Why?
Data Anonymization
1
2019
1
0.180
Why?
Telemedicine
2
2020
165
0.180
Why?
Tumor Burden
1
2021
288
0.180
Why?
Guideline Adherence
2
2013
221
0.180
Why?
Drug Repositioning
1
2019
22
0.180
Why?
Thrombocytopenia
13
2004
181
0.180
Why?
Fetus
1
2000
226
0.180
Why?
Public Opinion
1
2019
43
0.180
Why?
Ethics, Medical
3
2012
306
0.180
Why?
Bevacizumab
3
2017
279
0.180
Why?
Remote Consultation
1
2019
16
0.180
Why?
Aminoglycosides
1
1999
32
0.180
Why?
International Cooperation
2
2020
126
0.170
Why?
Chromatography, High Pressure Liquid
7
1998
313
0.170
Why?
Transcriptome
3
2022
573
0.170
Why?
High-Throughput Nucleotide Sequencing
2
2019
450
0.170
Why?
Patients
2
2019
102
0.170
Why?
Glucuronosyltransferase
3
2014
184
0.170
Why?
Carcinoma, Renal Cell
3
2004
420
0.170
Why?
Health Services Research
1
2019
135
0.170
Why?
Peptides
4
1985
639
0.170
Why?
Publishing
1
2019
89
0.170
Why?
Testicular Neoplasms
4
1992
104
0.170
Why?
Food-Drug Interactions
2
2013
18
0.170
Why?
Program Development
2
2009
124
0.170
Why?
Lymphatic Metastasis
6
2013
480
0.170
Why?
Pharmaceutical Preparations
1
2019
92
0.170
Why?
Legislation, Drug
1
2018
7
0.160
Why?
Government Regulation
1
2018
48
0.160
Why?
Self Report
1
2019
280
0.160
Why?
Health Information Management
1
2017
1
0.160
Why?
Medical Records
1
2018
120
0.160
Why?
Drug Resistance, Multiple
1
1997
20
0.160
Why?
Adverse Drug Reaction Reporting Systems
1
2017
22
0.160
Why?
Medicare
5
2014
397
0.160
Why?
Eligibility Determination
1
2017
31
0.160
Why?
Genotyping Techniques
1
2018
68
0.160
Why?
DNA Mismatch Repair
2
2018
52
0.150
Why?
DNA Methylation
1
2002
619
0.150
Why?
Retrospective Studies
12
2022
8342
0.150
Why?
Proportional Hazards Models
6
2021
855
0.150
Why?
Prospective Studies
13
2022
4156
0.150
Why?
Cardiovascular Diseases
3
2021
823
0.150
Why?
Kaplan-Meier Estimate
5
2019
857
0.150
Why?
Tamoxifen
1
1997
167
0.150
Why?
Drug Interactions
7
2007
248
0.150
Why?
Immunologic Factors
1
2018
170
0.140
Why?
Stakeholder Participation
1
2016
19
0.140
Why?
Oncology Nursing
1
2016
8
0.140
Why?
Insurance Claim Review
3
2008
41
0.140
Why?
Ovary
3
1989
250
0.140
Why?
Area Under Curve
8
2007
333
0.140
Why?
Meta-Analysis as Topic
1
2015
88
0.140
Why?
Interferon-alpha
5
2004
232
0.140
Why?
Salvage Therapy
2
2010
232
0.130
Why?
Radiation Oncology
1
2017
119
0.130
Why?
Quinazolines
4
2003
218
0.130
Why?
Age Factors
5
2016
1831
0.130
Why?
Bone Marrow Diseases
2
1993
40
0.130
Why?
Aging
2
2012
688
0.130
Why?
Depsipeptides
1
2015
29
0.130
Why?
Frail Elderly
2
2014
71
0.130
Why?
Radiation-Sensitizing Agents
2
1992
94
0.130
Why?
GTP Phosphohydrolases
1
2015
71
0.130
Why?
Asia
1
2015
94
0.130
Why?
Fluorodeoxyglucose F18
2
2007
137
0.130
Why?
Liver
3
2004
1223
0.130
Why?
Epidemiologic Methods
1
2015
59
0.130
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
2
2004
111
0.130
Why?
Observational Studies as Topic
1
2015
45
0.130
Why?
Diagnostic Imaging
1
2019
468
0.130
Why?
Floxuridine
2
1993
11
0.130
Why?
Phenotype
6
2014
2362
0.130
Why?
Health Care Reform
1
2016
90
0.130
Why?
Angiogenesis Inhibitors
1
2017
309
0.130
Why?
Trimetrexate
3
2002
4
0.130
Why?
Folic Acid Antagonists
2
1992
19
0.130
Why?
Dacarbazine
2
1998
102
0.130
Why?
Leukopenia
9
1997
65
0.120
Why?
Lymphoma
5
2004
262
0.120
Why?
Cohort Studies
8
2019
2738
0.120
Why?
Animals
18
2013
26414
0.120
Why?
Adolescent
10
2018
8905
0.120
Why?
Drug Resistance, Neoplasm
4
2016
589
0.120
Why?
Bone Marrow
9
2001
431
0.120
Why?
DNA Mutational Analysis
1
2015
526
0.120
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2015
136
0.120
Why?
Disease Management
3
2021
326
0.120
Why?
Exons
1
2015
450
0.120
Why?
Tegafur
4
2001
17
0.120
Why?
Geriatrics
1
2014
61
0.120
Why?
Kallikreins
1
2013
47
0.120
Why?
Clinical Trials, Phase I as Topic
4
2016
149
0.120
Why?
Pediatrics
1
2018
343
0.120
Why?
Unnecessary Procedures
1
2013
51
0.120
Why?
Anthracenes
1
1993
15
0.110
Why?
Multivariate Analysis
5
2013
995
0.110
Why?
Heart Failure
2
2021
1192
0.110
Why?
Naphthalimides
7
1999
17
0.110
Why?
Device Approval
1
2013
13
0.110
Why?
Anilides
1
2013
46
0.110
Why?
Topotecan
4
1998
45
0.110
Why?
Multimodal Imaging
1
2013
109
0.110
Why?
Gonads
1
1992
19
0.110
Why?
Medication Adherence
1
2014
129
0.110
Why?
Organophosphonates
7
1999
50
0.110
Why?
Obesity
2
2015
955
0.110
Why?
Sepsis
1
1996
299
0.110
Why?
Recombinant Proteins
8
2003
1012
0.110
Why?
Adenine
7
1999
85
0.110
Why?
Kidney Diseases
4
2003
417
0.110
Why?
Validation Studies as Topic
1
2012
16
0.110
Why?
Antiemetics
1
2013
98
0.110
Why?
Neuroendocrine Tumors
1
2014
100
0.110
Why?
Antibodies, Monoclonal, Murine-Derived
3
2016
78
0.110
Why?
Young Adult
4
2019
5918
0.110
Why?
Program Evaluation
1
2013
295
0.110
Why?
Thymidylate Synthase
2
2001
13
0.110
Why?
Healthcare Disparities
1
2016
361
0.110
Why?
Research Subjects
2
2011
73
0.110
Why?
Patient Advocacy
1
2012
49
0.100
Why?
Injections, Intravenous
4
2004
243
0.100
Why?
Echinomycin
1
1991
2
0.100
Why?
Sequence Analysis, DNA
2
2019
852
0.100
Why?
Magnesium Deficiency
2
1982
5
0.100
Why?
Prostate-Specific Antigen
1
2013
345
0.100
Why?
Hepatectomy
2
2014
160
0.100
Why?
Premenopause
1
2011
54
0.100
Why?
Interleukin-17
1
2011
98
0.100
Why?
Pharmacoepidemiology
1
2010
6
0.100
Why?
Cancer Care Facilities
1
2011
28
0.100
Why?
Tissue Array Analysis
1
2011
124
0.100
Why?
Carbazoles
1
2011
51
0.100
Why?
Diphosphonates
1
2011
36
0.100
Why?
Primary Ovarian Insufficiency
1
2011
18
0.100
Why?
Chemoprevention
1
2011
91
0.100
Why?
Geriatric Assessment
1
2012
166
0.100
Why?
Bone Density Conservation Agents
1
2011
45
0.100
Why?
Molecular Biology
1
2011
89
0.100
Why?
Tetrahydrofolate Dehydrogenase
4
1985
32
0.100
Why?
Mandatory Testing
1
2010
3
0.100
Why?
Stereoisomerism
5
1990
102
0.090
Why?
Remission Induction
9
1997
721
0.090
Why?
Standard of Care
1
2011
78
0.090
Why?
B7-H1 Antigen
2
2022
249
0.090
Why?
Formyltetrahydrofolates
1
1990
1
0.090
Why?
Imidazoles
1
2011
162
0.090
Why?
Algorithms
4
2015
1823
0.090
Why?
Cyclooxygenase 2
1
2010
99
0.090
Why?
Bone Density
1
2011
207
0.090
Why?
Thymidine
2
1986
58
0.090
Why?
Infertility, Male
1
1989
24
0.090
Why?
Pyrroles
1
2010
184
0.090
Why?
Stomatitis
5
2004
30
0.090
Why?
Splenectomy
1
1989
82
0.090
Why?
Peritoneal Neoplasms
1
1990
175
0.090
Why?
Adjuvants, Immunologic
1
2010
166
0.090
Why?
Software Design
1
2008
17
0.090
Why?
Membrane Proteins
1
2015
1192
0.080
Why?
Attitude
1
2009
123
0.080
Why?
Radiation Injuries
1
1989
155
0.080
Why?
France
2
2020
47
0.080
Why?
Mortality
1
2009
148
0.080
Why?
Qualitative Research
1
2009
253
0.080
Why?
Filgrastim
3
2003
56
0.080
Why?
Databases, Genetic
1
2009
259
0.080
Why?
Genitalia, Male
1
1988
24
0.080
Why?
Genitalia, Female
1
1988
25
0.080
Why?
Tomography, X-Ray Computed
2
2019
2557
0.080
Why?
Carcinoma, Squamous Cell
6
1992
1075
0.080
Why?
Double-Blind Method
4
2011
1812
0.080
Why?
Carcinoembryonic Antigen
1
2007
41
0.080
Why?
Kinetics
6
1990
1512
0.080
Why?
Glycolipids
1
2007
29
0.080
Why?
Half-Life
4
2004
96
0.080
Why?
Leadership
1
2009
132
0.080
Why?
SEER Program
3
2016
181
0.080
Why?
Physician-Patient Relations
2
2011
608
0.080
Why?
Genotype
4
2014
1845
0.080
Why?
Product Surveillance, Postmarketing
1
2007
37
0.080
Why?
Sex
1
1987
6
0.080
Why?
Ketoconazole
1
2007
25
0.080
Why?
Palliative Care
1
2009
254
0.080
Why?
Carboplatin
3
2008
286
0.080
Why?
Radiotherapy
1
1989
326
0.080
Why?
Stomach Neoplasms
3
1994
264
0.080
Why?
Nogalamycin
1
1986
2
0.070
Why?
Academic Medical Centers
1
2009
375
0.070
Why?
Antibiotics, Antineoplastic
3
2003
110
0.070
Why?
Bilirubin
3
2007
124
0.070
Why?
Recreation
1
2006
7
0.070
Why?
Signal Transduction
2
2015
3222
0.070
Why?
Drug Combinations
2
2001
221
0.070
Why?
Leukemia, Hairy Cell
1
1987
186
0.070
Why?
Physical Exertion
1
2006
39
0.070
Why?
Daunorubicin
1
1986
78
0.070
Why?
Metabolic Clearance Rate
4
2004
121
0.070
Why?
Glycoproteins
1
2007
234
0.070
Why?
Antifungal Agents
1
2007
117
0.070
Why?
Risk
2
2010
672
0.070
Why?
Interferon Type I
1
1987
175
0.070
Why?
Canada
2
2017
203
0.070
Why?
Pyrazines
2
1998
84
0.070
Why?
Infertility
2
1989
36
0.070
Why?
Bleomycin
5
1998
98
0.070
Why?
Fatigue
4
2011
173
0.070
Why?
Oligonucleotides, Antisense
1
2005
69
0.070
Why?
Peripheral Nervous System Diseases
1
2006
85
0.070
Why?
Neoplasm Invasiveness
2
2004
540
0.070
Why?
Phenobarbital
1
2004
33
0.060
Why?
Genetic Predisposition to Disease
1
2014
2254
0.060
Why?
Incidence
1
2009
1561
0.060
Why?
Pilot Projects
2
2019
834
0.060
Why?
Maytansine
1
2004
9
0.060
Why?
Regression Analysis
2
1997
593
0.060
Why?
Feasibility Studies
2
2021
750
0.060
Why?
Cognition Disorders
1
2006
236
0.060
Why?
Urogenital Neoplasms
3
2008
22
0.060
Why?
Nurses
1
2004
39
0.060
Why?
Motor Activity
1
2006
326
0.060
Why?
Antibody Specificity
1
2003
129
0.060
Why?
Idoxuridine
2
1993
16
0.060
Why?
Hypnotics and Sedatives
1
2004
124
0.060
Why?
Magnesium
3
1982
177
0.060
Why?
Exercise
1
2006
314
0.060
Why?
Child
6
2018
6866
0.060
Why?
Follow-Up Studies
5
2004
3608
0.060
Why?
Patient Compliance
3
2001
224
0.060
Why?
Azirines
1
1982
3
0.050
Why?
Aziridines
1
1982
9
0.050
Why?
Acetylation
4
1996
121
0.050
Why?
Secondary Prevention
1
2003
161
0.050
Why?
Benzoquinones
1
1982
27
0.050
Why?
DNA Adducts
1
2002
20
0.050
Why?
CTLA-4 Antigen
1
2022
135
0.050
Why?
Minority Groups
1
2023
128
0.050
Why?
Insulin
2
1985
1159
0.050
Why?
Colonic Polyps
1
2003
126
0.050
Why?
Oxonic Acid
1
2001
8
0.050
Why?
Antigens, Neoplasm
1
2003
324
0.050
Why?
Aminoquinolines
1
2001
17
0.050
Why?
Indenes
1
2001
9
0.050
Why?
Immunohistochemistry
2
2004
1751
0.050
Why?
Liver Diseases
1
2003
236
0.050
Why?
Oxidoreductases Acting on CH-CH Group Donors
1
2001
9
0.050
Why?
Topoisomerase II Inhibitors
1
2001
26
0.050
Why?
Intercalating Agents
2
1993
12
0.050
Why?
Patient Outcome Assessment
1
2021
83
0.050
Why?
Lymphoma, Follicular
1
2001
70
0.050
Why?
Receptor Protein-Tyrosine Kinases
1
2002
153
0.050
Why?
Colonoscopy
1
2003
259
0.050
Why?
Leukemia, Myeloid
1
2002
249
0.050
Why?
World Health Organization
1
2020
102
0.050
Why?
Piperazines
1
2022
271
0.050
Why?
Acute Disease
1
2002
819
0.050
Why?
Cause of Death
1
2001
276
0.050
Why?
Specimen Handling
2
2011
98
0.050
Why?
Neoplasm Proteins
1
2003
532
0.050
Why?
Drug Therapy, Combination
4
2004
894
0.050
Why?
Health Insurance Portability and Accountability Act
1
2019
7
0.050
Why?
Cell Line
6
1988
2462
0.050
Why?
Kidney Tubular Necrosis, Acute
1
1979
10
0.040
Why?
Analysis of Variance
2
1999
912
0.040
Why?
DNA Repair
1
2002
356
0.040
Why?
Morals
1
2020
92
0.040
Why?
Policy Making
1
2019
62
0.040
Why?
Prenatal Exposure Delayed Effects
1
2000
152
0.040
Why?
Infection Control
1
2020
114
0.040
Why?
Immunosuppressive Agents
1
2004
973
0.040
Why?
Gallbladder Neoplasms
1
1999
22
0.040
Why?
Melphalan
1
1999
97
0.040
Why?
Kidney Tubules
1
1979
94
0.040
Why?
Biological Availability
1
1998
91
0.040
Why?
Drug Prescriptions
1
2019
140
0.040
Why?
Gas Chromatography-Mass Spectrometry
1
1998
40
0.040
Why?
Microsatellite Instability
1
2018
40
0.040
Why?
Delphi Technique
1
2018
73
0.040
Why?
Insurance Coverage
1
2019
108
0.040
Why?
Radiotherapy, Adjuvant
2
1997
291
0.040
Why?
Common Data Elements
1
2017
1
0.040
Why?
Bile Duct Neoplasms
1
1999
75
0.040
Why?
Maximum Tolerated Dose
3
2004
270
0.040
Why?
Diagnostic Errors
1
2019
158
0.040
Why?
Pathology, Clinical
1
2018
33
0.040
Why?
Polymorphism, Genetic
1
2002
819
0.040
Why?
Observation
2
2008
37
0.040
Why?
Developed Countries
1
2017
24
0.040
Why?
Databases, Nucleic Acid
1
2017
41
0.040
Why?
Endpoint Determination
2
2010
60
0.040
Why?
Body Weight
2
1996
458
0.040
Why?
Hospitalization
2
2016
836
0.040
Why?
Annual Reports as Topic
1
2017
5
0.040
Why?
Developing Countries
1
2017
69
0.040
Why?
Serum Albumin
2
1995
129
0.040
Why?
Nausea
3
2004
175
0.040
Why?
Professional Competence
1
2017
68
0.040
Why?
Central Nervous System Neoplasms
2
2008
80
0.040
Why?
Pregnancy
2
2000
2876
0.040
Why?
Genital Neoplasms, Female
2
2008
107
0.040
Why?
Leukocyte Count
4
1996
219
0.040
Why?
Lung
1
2022
1149
0.040
Why?
Sex Factors
2
2016
1043
0.040
Why?
Taxoids
1
2016
129
0.040
Why?
Spermatogenesis
2
1989
37
0.030
Why?
Insurance, Health
1
2016
153
0.030
Why?
Israel
1
2015
55
0.030
Why?
Spain
1
2015
33
0.030
Why?
Asthenia
2
1985
4
0.030
Why?
Cross-Sectional Studies
1
2020
1587
0.030
Why?
Acute Kidney Injury
1
1979
291
0.030
Why?
Federal Government
1
2015
28
0.030
Why?
Neoplasms, Unknown Primary
1
1994
15
0.030
Why?
Digestive System
3
1986
42
0.030
Why?
ROC Curve
2
2008
747
0.030
Why?
Outpatients
2
2000
93
0.030
Why?
Rare Diseases
1
2015
58
0.030
Why?
Protein Binding
3
1985
1450
0.030
Why?
Cladribine
1
1994
35
0.030
Why?
Research Personnel
1
2015
66
0.030
Why?
Cyclohexanecarboxylic Acids
1
1994
17
0.030
Why?
Vidarabine Phosphate
1
1994
5
0.030
Why?
Congresses as Topic
1
2015
116
0.030
Why?
Educational Status
1
2014
185
0.030
Why?
Salivary Gland Neoplasms
1
1994
66
0.030
Why?
Socioeconomic Factors
1
2016
566
0.030
Why?
Antineoplastic Agents, Hormonal
1
2015
150
0.030
Why?
Oligonucleotide Array Sequence Analysis
1
2016
684
0.030
Why?
Therapeutic Human Experimentation
1
1993
20
0.030
Why?
Nontherapeutic Human Experimentation
1
1993
20
0.030
Why?
Anti-Bacterial Agents
1
1999
732
0.030
Why?
Blood Cell Count
1
1993
79
0.030
Why?
Neoplastic Cells, Circulating
1
2014
69
0.030
Why?
Genome-Wide Association Study
2
2011
1601
0.030
Why?
Peer Review, Research
1
2013
36
0.030
Why?
Electrocardiography
2
1993
475
0.030
Why?
Pharmacy
1
2013
7
0.030
Why?
Aminopterin
1
1992
5
0.030
Why?
Astrocytoma
1
1993
82
0.030
Why?
Peptide Biosynthesis
2
1982
17
0.030
Why?
Thiophenes
1
1992
48
0.030
Why?
Statistics as Topic
1
1993
237
0.030
Why?
Methyltransferases
1
1994
181
0.030
Why?
Monocytes
1
1994
214
0.030
Why?
Chemistry, Pharmaceutical
1
1992
59
0.030
Why?
Health Services for the Aged
1
2012
27
0.030
Why?
Neoplasm Grading
1
2013
352
0.030
Why?
Neoadjuvant Therapy
1
2014
310
0.030
Why?
Models, Biological
5
2002
1740
0.030
Why?
Glioblastoma
1
1993
253
0.020
Why?
Intestinal Absorption
2
2002
123
0.020
Why?
Sensitivity and Specificity
2
2006
1979
0.020
Why?
Creatinine
2
2003
335
0.020
Why?
Respiratory Insufficiency
1
1993
149
0.020
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
874
0.020
Why?
Public Sector
1
2010
12
0.020
Why?
Injections, Intraperitoneal
1
1990
102
0.020
Why?
Private Sector
1
2010
19
0.020
Why?
Drug Resistance
2
1993
256
0.020
Why?
Amino Acid Substitution
1
2011
339
0.020
Why?
Cells, Cultured
4
1985
2798
0.020
Why?
Anorexia
2
2001
30
0.020
Why?
Deoxyuracil Nucleotides
1
1990
5
0.020
Why?
Prostaglandins
1
2010
42
0.020
Why?
Mechlorethamine
2
1998
11
0.020
Why?
Linkage Disequilibrium
1
2011
473
0.020
Why?
Buffers
1
1990
26
0.020
Why?
Procarbazine
2
1998
40
0.020
Why?
Fever
1
2011
123
0.020
Why?
Cell-Free System
1
1990
51
0.020
Why?
Pyrimidines
1
1992
370
0.020
Why?
Vincristine
2
1998
111
0.020
Why?
Alleles
2
2004
1124
0.020
Why?
Immunologic Deficiency Syndromes
1
1989
47
0.020
Why?
Prednisone
2
1998
255
0.020
Why?
Spermatozoa
1
1989
61
0.020
Why?
Cell Membrane
2
1983
664
0.020
Why?
Survivors
1
2010
225
0.020
Why?
Bromodeoxyuridine
1
1988
57
0.020
Why?
Arrhythmias, Cardiac
1
1990
187
0.020
Why?
Drug Therapy
1
1989
70
0.020
Why?
Thoracic Neoplasms
1
2008
64
0.020
Why?
Pain
1
2011
387
0.020
Why?
Serum Albumin, Bovine
1
1988
45
0.020
Why?
Bone Neoplasms
1
2010
322
0.020
Why?
Lipid Droplets
1
2007
16
0.020
Why?
Antibodies, Anti-Idiotypic
1
2007
44
0.020
Why?
Laryngeal Neoplasms
1
1988
89
0.020
Why?
Silicon Dioxide
1
1988
39
0.020
Why?
Kidney
2
1986
1226
0.020
Why?
Ambulatory Care
1
1989
174
0.020
Why?
Hypothyroidism
1
1989
231
0.020
Why?
DNA, Recombinant
1
1987
67
0.020
Why?
Biotransformation
2
1990
50
0.020
Why?
Hormone Replacement Therapy
1
2007
77
0.020
Why?
Lung Diseases
1
1989
261
0.020
Why?
Immunity, Cellular
1
2007
176
0.020
Why?
Sarcoma
1
2008
210
0.020
Why?
Menogaril
1
1986
3
0.020
Why?
Follicle Stimulating Hormone
1
1987
147
0.020
Why?
Bone Marrow Transplantation
1
1988
285
0.020
Why?
Luteinizing Hormone
1
1987
167
0.020
Why?
Thymine
1
1986
17
0.020
Why?
Ethics Committees, Research
1
2006
33
0.020
Why?
Pneumonectomy
1
2008
195
0.020
Why?
Inpatients
1
1989
292
0.020
Why?
Carcinoma, Bronchogenic
1
1985
30
0.020
Why?
Testosterone
1
1987
268
0.020
Why?
Clone Cells
1
1985
213
0.020
Why?
Oligodeoxyribonucleotides
1
2005
126
0.020
Why?
Phenylenediamines
1
2004
5
0.020
Why?
Calcium
1
1990
1143
0.020
Why?
Peripheral Blood Stem Cell Transplantation
1
2005
67
0.020
Why?
Anemia
2
2003
128
0.020
Why?
Transaminases
1
2004
34
0.020
Why?
Nucleotides
1
1985
95
0.020
Why?
Platelet Count
1
1984
92
0.020
Why?
Nurse-Patient Relations
1
2004
13
0.020
Why?
Von Hippel-Lindau Tumor Suppressor Protein
1
2004
15
0.020
Why?
Histone Deacetylase Inhibitors
1
2004
85
0.020
Why?
Tissue Distribution
2
1982
290
0.020
Why?
Mice
2
1996
11193
0.020
Why?
Dogs
1
1985
682
0.020
Why?
Microtubules
1
2004
117
0.020
Why?
Benzamides
1
2004
225
0.010
Why?
Gastrointestinal Diseases
1
1985
145
0.010
Why?
Medicaid
1
2006
211
0.010
Why?
Models, Theoretical
1
1986
476
0.010
Why?
Diarrhea
1
2004
180
0.010
Why?
Prostatic Neoplasms
1
2015
1696
0.010
Why?
Polymorphism, Single Nucleotide
1
2011
2345
0.010
Why?
Hematologic Neoplasms
1
2006
327
0.010
Why?
CD56 Antigen
1
2002
18
0.010
Why?
Chromium
1
2002
17
0.010
Why?
Ubiquitin-Protein Ligases
1
2004
165
0.010
Why?
Dysgerminoma
1
1982
7
0.010
Why?
Immunoenzyme Techniques
1
2002
303
0.010
Why?
Nitrosourea Compounds
1
1982
9
0.010
Why?
Therapeutic Equivalency
1
2002
12
0.010
Why?
Electrolytes
1
1982
52
0.010
Why?
Glucuronides
1
2002
34
0.010
Why?
Interleukin-2
1
2002
245
0.010
Why?
Tumor Suppressor Proteins
1
2004
279
0.010
Why?
Vascular Endothelial Growth Factor A
1
2004
407
0.010
Why?
Population
1
2002
35
0.010
Why?
Muscles
1
1982
190
0.010
Why?
Genes, bcl-2
1
2001
16
0.010
Why?
In Situ Hybridization, Fluorescence
1
2002
348
0.010
Why?
Skin Neoplasms
1
2006
541
0.010
Why?
Amenorrhea
1
1981
27
0.010
Why?
Nucleic Acids
1
1982
30
0.010
Why?
Sodium Azide
1
1981
5
0.010
Why?
Azides
1
1981
11
0.010
Why?
Uric Acid
1
1982
138
0.010
Why?
Diagnosis, Differential
1
2006
1552
0.010
Why?
Dihydrouracil Dehydrogenase (NAD+)
1
2001
1
0.010
Why?
Demography
1
2002
177
0.010
Why?
Biological Transport, Active
1
1981
101
0.010
Why?
Chi-Square Distribution
1
2002
362
0.010
Why?
Cell Division
1
1982
696
0.010
Why?
Hormones
1
1981
140
0.010
Why?
Killer Cells, Natural
1
2002
265
0.010
Why?
Haplorhini
1
1981
81
0.010
Why?
Cross-Over Studies
1
2002
397
0.010
Why?
Gene Rearrangement
1
2001
169
0.010
Why?
Flow Cytometry
1
2002
674
0.010
Why?
Ovulation
1
1980
67
0.010
Why?
Alkylating Agents
1
1980
32
0.010
Why?
Gallium Radioisotopes
1
1980
31
0.010
Why?
Estradiol
1
1981
249
0.010
Why?
Glomerular Filtration Rate
1
1982
384
0.010
Why?
Binding Sites
1
1983
1097
0.010
Why?
Temperature
1
1981
390
0.010
Why?
Neoplasms, Experimental
1
1981
269
0.010
Why?
Drug Hypersensitivity
1
1979
38
0.010
Why?
Infusion Pumps
2
1989
25
0.010
Why?
Cell Differentiation
1
1985
1434
0.010
Why?
Radiotherapy Dosage
2
1992
467
0.010
Why?
Hearing
1
1979
59
0.010
Why?
Kidney Function Tests
1
1979
124
0.010
Why?
Hypoxia
1
2004
635
0.010
Why?
Alkyl and Aryl Transferases
1
1998
15
0.010
Why?
Random Allocation
2
1989
332
0.010
Why?
Cell Count
1
1998
193
0.010
Why?
Leukocytes, Mononuclear
1
1998
196
0.010
Why?
Isotretinoin
1
1997
23
0.010
Why?
Antidotes
1
1997
23
0.010
Why?
Injections, Subcutaneous
1
1997
117
0.010
Why?
Tumor Cells, Cultured
2
1988
1039
0.010
Why?
Brain
1
1986
2196
0.010
Why?
Magnetic Resonance Imaging
1
2007
3316
0.010
Why?
Linear Models
1
1996
416
0.010
Why?
Cyclohexenes
1
1994
5
0.010
Why?
Benzofurans
1
1994
8
0.010
Why?
Blindness
1
1994
41
0.010
Why?
Rats
1
1981
3966
0.010
Why?
Consent Forms
1
1993
11
0.010
Why?
Personal Autonomy
1
1993
111
0.010
Why?
Mouth Mucosa
1
1993
66
0.010
Why?
Pancoast Syndrome
1
1990
2
0.010
Why?
Blood Transfusion
1
1991
158
0.010
Why?
Trifluoperazine
1
1990
10
0.010
Why?
Diltiazem
1
1990
17
0.010
Why?
Nifedipine
1
1990
28
0.010
Why?
Verapamil
1
1990
48
0.010
Why?
Biological Transport
1
1990
395
0.010
Why?
Leukemia L1210
1
1988
12
0.010
Why?
Radiotherapy, High-Energy
1
1988
49
0.010
Why?
Whole-Body Irradiation
1
1988
63
0.000
Why?
Attitude to Health
1
1989
219
0.000
Why?
Hydrogen-Ion Concentration
1
1988
492
0.000
Why?
Transplantation, Autologous
1
1988
328
0.000
Why?
DNA Damage
1
1988
362
0.000
Why?
Models, Statistical
1
1989
573
0.000
Why?
Chromatography, Gel
1
1982
103
0.000
Why?
False Negative Reactions
1
1980
63
0.000
Why?
Lymphography
1
1980
27
0.000
Why?
Evaluation Studies as Topic
1
1980
270
0.000
Why?
False Positive Reactions
1
1980
216
0.000
Why?
Dactinomycin
1
1979
35
0.000
Why?
Radionuclide Imaging
1
1980
218
0.000
Why?
Nervous System
1
1979
86
0.000
Why?
Heart
1
1979
534
0.000
Why?
Schilsky's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (773)
Explore
_
Co-Authors (27)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_